Wallace M S
Department of Anesthesiology, University of California, San Diego School of Medicine, La Jolla, CA 92093, USA.
Curr Pain Headache Rep. 2001 Apr;5(2):138-50. doi: 10.1007/s11916-001-0082-2.
Neuropathic pain, or pain after nervous system injury, can be very refractory to pharmacologic interventions. Through a better understanding of the pathophysiology of neuropathic pain, it has been suggested that nonopioid agents, such as antidepressants and anticonvulsants, may be more efficacious in the treatment of neuropathic pain than common analgesics, such as opioids or nonsteroidal anti-inflammatory drugs. However, this has not been consistently demonstrated in clinical studies. Conversely, many confounding factors of neuropathic pain make it difficult to interpret clinical studies. Therefore, we must develop a better understanding of the preclinical models of neuropathic pain to better understand the application of new and old drugs to the human neuropathic pain state. This article provides an overview of the commonly used preclinical neuropathic pain models, followed by a summary of the efficacy of currently available agents in preclinical pain models and human correlates.
神经性疼痛，即神经系统损伤后的疼痛，对药物干预可能非常难治。通过对神经性疼痛病理生理学的更好理解，有人提出非阿片类药物，如抗抑郁药和抗惊厥药，在治疗神经性疼痛方面可能比常见的镇痛药，如阿片类药物或非甾体抗炎药更有效。然而，这在临床研究中并未得到一致证实。相反，神经性疼痛的许多混杂因素使得难以解释临床研究结果。因此，我们必须更好地理解神经性疼痛的临床前模型，以便更好地理解新药和旧药在人类神经性疼痛状态中的应用。本文概述了常用的临床前神经性疼痛模型，随后总结了现有药物在临床前疼痛模型中的疗效以及与人类的相关性。
